Targeting lipoprotein (a): an evolving therapeutic landscape.
Robust epidemiologic and genetic studies have solidified the role of lipoprotein (a) [Lp(a)] as an independent and causal risk factor for cardiovascular disease. The increased cardiovascular risk of Lp(a) is mediated through both proatherogenic and prothrombotic/antifibrinolytic mechanisms. Several societies recommend Lp(a) screening for patients with high cardiovascular risk, although no consensus exists on the management of patients with elevated Lp(a). However, numerous pharmacologic approaches are being evaluated that have the potential to reduce Lp(a) and will be the focus of this review. The majority of these interventions have been developed for other lipid-lowering indications, but also lower Lp(a). There are also novel therapies in development that specifically target Lp(a). The efficacy of these therapies varies, and their role in the evolving lipoprotein therapeutic landscape has yet to be determined. Nevertheless, targeted Lp(a) reduction is certainly intriguing and will likely continue to be an active area of investigation in the future.
Department of Medicine, Thomas Jefferson University Hospital, 1025 Walnut Street, Room 805, Philadelphia, PA, 19107, USA, Lillian.man@jefferson.edu.
Lillian C
LC
Man
Erik
E
Kelly
Danielle
D
Duffy
D002318:Cardiovascular Diseases / Q000097:blood / Q000235:genetics*; D019468:Disease Management; D006801:Humans; D017270:Lipoprotein(a) / Q000235:genetics* / Q000378:metabolism
D017270:Lipoprotein(a)